Stock Analiz

Aspen Aerogels Inc. ASPN

RETAIL: Building Materials · IPO 2014 · data as of November 13, 2026

$5.58Market cap $464M
Open the interactive analysis →

Aspen Aerogels Inc. (ASPN) is a consumer discretionary company listed in the US with a market value of about $464M. In the twelve months to September 30, 2026 it had revenue of $214M and net income of -$130M, a net margin of -60.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 23.3, 5-year revenue growth of 22% a year, a 5-year average ROIC of -26%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 68% below the current price.

About Aspen Aerogels

Aspen Aerogels is listed in the US and classified in retail: building materials, IPO year 2014. Revenue went from $102M in 2014 to $271M in 2025, growth of about 9.3% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 109% over three years (dilution for shareholders). It spends 5% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth2/5
Track record1/5
Financial health3/5
Shareholder returns1/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF23.3
P/S2.2
P/B2.5
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield4.3%
Shareholder yield0.0%
Intrinsic value vs. price−68%

Growth and quality

Revenue growth (1 yr)-40.1%
Revenue growth (5 yrs, per year)22.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-47.3%
ROIC (5-yr avg.)-25.9%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$214M$271M$453M$239M$180M$122M$100M$139M$104M$112M$118M
Net income-$130M-$390M$13M-$46M-$83M-$37M-$22M-$15M-$34M-$19M-$12M
Free cash flow$20M-$5M-$41M-$218M-$272M-$32M-$13M-$3M-$12M-$11M-$14M
EPS (diluted)$-1.58$-4.73$0.17$-0.66$-2.10$-1.22$-0.83$-0.60$-1.45$-0.83$-0.52
Net margin-60.8%-143.7%2.9%-19.2%-45.9%-30.5%-21.8%-10.4%-33.0%-17.3%-10.2%
ROIC—-91.8%6.4%-7.8%-14.0%-22.3%-22.4%-16.6%-33.3%-14.4%-7.7%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 5 analysts is $7.75, 39% above the current price; targets range from $5.00 to $10.00; the consensus rating is “Buy”; expected EPS is $-0.27 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Aspen Aerogels stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 68% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Aspen Aerogels pay a dividend?

Not currently.

Is Aspen Aerogels a good stock to buy?

We do not give buy or sell advice. Aspen Aerogels scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.